New stock news | Jia Yin Biotechnology's Hong Kong IPO prospectus is invalid
The Hong Kong IPO prospectus filed by Exegenesis Bio Inc. (referred to as Jiayin Biology) on January 14, 2026, expires after 6 months on July 14, 2026.
Exegenesis Bio Inc. (referred to as Jiayin Bio) submitted its Hong Kong IPO prospectus on January 14, 2026, which expired after 6 months on July 14, 2026, with CICC acting as its exclusive sponsor.
According to the prospectus previously disclosed, Jiayin Bio is a biopharmaceutical company focusing on gene therapy and oligonucleotide drugs. According to data from Frost & Sullivan, the company has leading global delivery vector technology. As of the end of the fiscal year ending on December 31, 2024, the company had no revenue.
Related Articles
Zhongtai: Adhere to the mainline of technology and do not waver, the storage and CPU sectors have little room for downward adjustment.
Zhongtai listed banks look ahead to the semi-annual report of 2026: interest income supports revenue resilience, profit performance expected to remain stable.
New Stock News | Borgtech Electronics Submits Application to Hong Kong Stock Exchange Again, Becoming the Second Largest High-Performance Computing Power Supply Supplier in Mainland China.
Zhongtai: Adhere to the mainline of technology and do not waver, the storage and CPU sectors have little room for downward adjustment.
Zhongtai listed banks look ahead to the semi-annual report of 2026: interest income supports revenue resilience, profit performance expected to remain stable.
New Stock News | Borgtech Electronics Submits Application to Hong Kong Stock Exchange Again, Becoming the Second Largest High-Performance Computing Power Supply Supplier in Mainland China.
RECOMMEND
